Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space.

Keros Therapeutics announced the first patient dosing in its phase II study evaluating rinvatercept for Duchenne muscular dystrophy (DMD). The study will assess safety, tolerability, and functional improvements, with initial data expected in H1 2027. The company is also advancing rinvatercept development for ALS treatment and has a licensing agreement with Takeda Pharmaceutical for its second candidate, elritercept, with potential milestone payments exceeding $1.1 billion.

Keros Therapeutics reported a Q2 2026 loss of $1.45 per share, missing consensus estimates, with revenues falling to zero from $18.2 million year-over-year. The company has no marketed products and is focusing on pipeline development. With $257.6 million in cash, the company expects runway into H1 2028. The stock received a Zacks Rank #3 (Hold) rating with an F VGM Score.

DelveInsight's report highlights a robust DMD clinical trial pipeline with 70+ active players developing 75+ pipeline drugs. Key companies including Capricor, Solid Biosciences, Roche, Dyne Therapeutics, and BioMarin Pharmaceutical are advancing promising therapies targeting dystrophin expression and gene transfer. Approximately 6+ drugs are in late-stage development, with recent FDA designations granted to multiple candidates including AAV-SERCA2a and PBGENE-DMD, signaling strong momentum in addressing the high unmet need for disease-modifying DMD treatments.

Keros Therapeutics presented Phase 1 clinical trial data for rinvatercept (KER-065), a ligand trap designed to inhibit myostatin and activin A for treating neuromuscular diseases. The drug demonstrated good tolerability with no serious adverse events, increased muscle mass, decreased fat mass, and increased bone mineral density. Proteomic analysis confirmed target engagement and mechanism of action. The company plans to advance rinvatercept into two Phase 2 trials for Duchenne muscular dystrophy (DMD) and amyotrophic lateral sclerosis (ALS).

Keros Therapeutics completed its cash tender offer to repurchase up to 10,950,165 shares of common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the company could purchase, resulting in a pro-rata allocation.

Keros Therapeutics completed a cash tender offer to repurchase up to 10,950,165 shares of its common stock at $17.75 per share, totaling approximately $194.4 million. More shares were tendered than the target, so shares will be accepted on a pro rata basis.

Over 25 pharmaceutical companies are developing TGF-β inhibitor drugs targeting oncology and fibrosis treatments, with promising pipeline therapies showing potential for addressing significant unmet medical needs.

Keros Therapeutics announced that leading independent proxy advisory firm Glass Lewis recommended that Keros stockholders vote 'FOR' all three of the company's director nominees for the upcoming Annual Meeting. Keros stated that the board is best equipped to oversee the strategic review process and execute on the ultimate outcome.

The blood cancer market is experiencing robust growth, driven by rising incidence rates and advancements in targeted therapies and immuno-oncology. Increasing adoption of CAR-T cell therapies, monoclonal antibodies, and personalized medicine is transforming treatment outcomes.

Harley-Davidson is exploring strategic alternatives for its financing unit, while Capri Holdings is selling Versace to Prada for $1.375 billion. Several other companies, including Impresoft, Keros Therapeutics, and Rivalry Corp., are also exploring strategic alternatives.

Keros Therapeutics has initiated a formal review of strategic alternatives, including a potential sale, after an investor gained an 11.2% stake in the company. The company has also adopted a stockholder rights plan.